|
1
|
Lei T, Zhao X, Jin S, Meng Q, Zhou H and
Zhang M: Discovery of potential bladder cancer biomarkers by
comparative urine proteomics and analysis. Clin Genitourin Cancer.
11:56–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meng Q, Lei T and Zhang M, Zhao J, Zhao XH
and Zhang M: Identification of proteins differentially expressed in
adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human
bladder cancer cell lines by proteome analysis. J Cancer Res Clin
Oncol. 139:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amling CL, Thrasher JB, Frazier HA, Dodge
RK, Robertson JE and Paulson DF: Radical cystectomy for stages Ta,
Tis and T1 transitional cell carcinoma of the bladder. J Urol.
151:31–35; discussion 35–36. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schuler G, Schuler-Thurner B and Steinman
RM: The use of dendritic cells in cancer immunotherapy. Curr Opin
Immunol. 15:138–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Si C, Zhang R, Wu T, Lu G, Hu Y, Zhang H,
Xu F, Wei P, Chen K, Tang H, et al: Dendritic cell-derived nitric
oxide inhibits the differentiation of effector dendritic cells.
Oncotarget. 7:74834–74845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma J, Usui Y, Takeuchi M, Okunuki Y,
Kezuka T, Zhang L, Mizota A and Goto H: Human uveal melanoma cells
inhibit the immunostimulatory function of dendritic cells. Exp Eye
Res. 91:491–499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma Y, Shurin GV, Peiyuan Z and Shurin MR:
Dendritic cells in the cancer microenvironment. J Cancer. 4:36–44.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pinzon-Charry A, Maxwell T and López JA:
Dendritic cell dysfunction in cancer: A mechanism for
immunosuppression. Immunol Cell Biol. 83:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joung YH, Na YM, Yoo YB, Darvin P, Sp N,
Kang DY, Kim SY, Kim HS, Choi YH, Lee HK, et al: Combination of
AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically
suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J
Oncol. 44:883–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bharadwaj U, Li M, Zhang R, Chen C and Yao
Q: Elevated interleukin-6 and G-CSF in human pancreatic cancer cell
conditioned medium suppress dendritic cell differentiation and
activation. Cancer Res. 67:5479–5488. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu S, Meng Q, Hu H and Zhang M:
Correlation of ANXA1 expression with drug resistance and relapse in
bladder cancer. Int J Clin Exp Pathol. 7:5538–5548. 2014.PubMed/NCBI
|
|
13
|
Xiu W, Ma J, Lei T, Zhang M and Zhou S:
Immunosuppressive effect of bladder cancer on function of dendritic
cells involving of Jak2/STAT3 pathway. Oncotarget. 7:63204–63214.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goyvaerts C and Breckpot K: Pros and cons
of antigen-presenting cell targeted tumor vaccines. J Immunol Res.
2015:7856342015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Tang H, Guo Z, An H, Zhu X, Song
W, Guo J, Huang X, Chen T, Wang J and Cao X: Splenic stroma drives
mature dendritic cells to differentiate into regulatory dendritic
cells. Nat Immunol. 5:1124–1133. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Svensson M, Maroof A, Ato M and Kaye PM:
Stromal cells direct local differentiation of regulatory dendritic
cells. Immunity. 21:805–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lizée G, Radvanyi LG, Overwijk WW and Hwu
P: Improving antitumor immune responses by circumventing
immunoregulatory cells and mechanisms. Clin Cancer Res.
12:4794–4803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Janco Tran JM, Lamichhane P, Karyampudi L
and Knutson KL: Tumor-infiltrating dendritic cells in cancer
pathogenesis. J Immunol. 194:2985–2991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harimoto H, Shimizu M, Nakagawa Y,
Nakatsuka K, Wakabayashi A, Sakamoto C and Takahashi H:
Inactivation of tumor-specific CD8+ CTLs by
tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol.
91:545–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krempski J, Karyampudi L, Behrens MD,
Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR and Knutson KL:
Tumor-infiltrating programmed death receptor-1+
dendritic cells mediate immune suppression in ovarian cancer. J
Immunol. 186:6905–6913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steinbrink K, Jonuleit H, Muller G,
Schuler G, Knop J and Enk AH: Interleukin-10-treated human
dendritic cells induce a melanoma-antigen-specific anergy in CD8(+)
T cells resulting in a failure to lyse tumor cells. Blood.
93:1634–1642. 1999.PubMed/NCBI
|
|
22
|
Steinbrink K, Graulich E, Kubsch S, Knop J
and Enk AH: CD4(+) and CD8(+) anergic T cells induced by
interleukin-10-treated human dendritic cells display
antigen-specific suppressor activity. Blood. 99:2468–2476. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hilkens CM, Kalinski P, de Boer M and
Kapsenberg ML: Human dendritic cells require exogenous
interleukin-12-inducing factors to direct the development of naive
T-helper cells toward the Th1 phenotype. Blood. 90:1920–1926.
1997.PubMed/NCBI
|
|
24
|
Jackson AM, Mulcahy LA, Zhu XW, O'Donnell
D and Patel PM: Tumour-mediated disruption of dendritic cell
function: Inhibiting the MEK1/2-p44/42 axis restores IL-12
production and Th1-generation. Int J Cancer. 123:623–632. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Collins M, Ling V and Carreno BM: The B7
family of immune-regulatory ligands. Genome Biol. 6:2232005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ludewig B, Graf D, Gelderblom HR, Becker
Y, Kroczek RA and Pauli G: Spontaneous apoptosis of dendritic cells
is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but
strongly enhanced by interleukin-10. Eur J Immunol. 25:1943–1950.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cirone M, Di Renzo L, Lotti LV, Conte V,
Trivedi P, Santarelli R, Gonnella R, Frati L and Faggioni A:
Primary effusion lymphoma cell death induced by bortezomib and AG
490 activates dendritic cells through CD91. PLoS One. 7:e317322012.
View Article : Google Scholar : PubMed/NCBI
|
